Issue link: https://nebusinessmedia.uberflip.com/i/935589
12 Hartford Business Journal • February 5, 2018 • www.HartfordBusiness.com Source: BioCT, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and IDEXX Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees statewide. (1) 244 Connecticut employees were laid off in 2016. (2) As of Sept. 2017, the company plans to move its headquarters to Boston, Mass., and keep 450 employees in New Haven. (3) Figure based on Jan. 2017 survey response, a March 2017 reduction in workforce and company news reports and announcements as of Sept. 2017. (4) In Dec. 2016, BMS announced previous plans to close Wallingford site by the end of 2018 are still in play, but the Connecticut development site that was to be built is no longer on the drawing board. (5) With an additional R&D operation in Branford. (6) Nonprofit residing on the campus of University of Connecticut Health Center. (7) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (8) Paris-based Sanofi acquired Protein Sciences Corp., effective Aug. 28, 2017; under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones. (9) Served as president & CEO from April 2010 until the recent Sanofi acquisition. (10) Acquired by Waltham, Mass.-based Thermo Fisher Scientific Inc. in March 2017. (11) Data from 2016 survey. (12) Jan. 19, 2018, announced expansion plans that will bring 30 additional jobs to New Haven. (13) Relocated from Shelton to Stamford. —Compiled by Stephanie R. Meagher. THE LIST Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of September 2017) FOCUS Largest bioscience/biotechnology companies in Connecticut (Ranked by number of employees as of September 2017) Rank Company Headquarters No. of employees in CT Focus Year founded Top executive 1 Pfizer Inc. 558 Eastern Point Road Groton, CT 06340 860-441-4100; www.pfizer.com New York, NY 3,000 Medicinal chemistry, pharmacokinetics, dynamics and metabolism, pharmaceutical sciences, clinical trials, drug safety, comparative medicine, regulatory 1849 Ian C. Read Chairman & CEO 2 Boehringer Ingelheim Pharmaceuticals Inc. 900 Ridgebury Road Ridgefield, CT 06877 800-344-3095; us.boehringer-ingelheim.com Ridgefield, CT 2,456 (1) Development and manufacture of human and animal healthcare products 1885 Paul R. Fonteyne President & CEO, USA 3 Alexion Pharmaceuticals Inc. (2) 100 College St. New Haven, CT 06510 475-230-2596; alexion.com New Haven, CT 850 (3) Severe and life-threatening rare disorders 1992 Ludwig N. Hantson CEO 4 Bristol-Myers Squibb Co. 5 Research Parkway Wallingford, CT 06492 203-677-6000; www.bms.com New York, NY 700 (4) BioPharma focused on discovering, developing and delivering medicines to help patients prevail over serious diseases such as cancer, cardiovascular disease, fibrotic diseases, genetically defined diseases, hepatitis C, HIV and rheumatoid arthritis 1858 Giovanni Caforio CEO 5 PerkinElmer Inc. 710 Bridgeport Ave. Shelton, CT 06484 (5) 203-925-4600; www.perkinelmer.com Waltham, MA 500 Detection, imaging, informatics and services innovating for a healthier world 1937 Robert F. Friel Chairman & CEO 6 The Jackson Laboratory for Genomic Medicine (6) 10 Discovery Drive Farmington, CT 06032 860-837-2474; www.jax.org Bar Harbor, ME 257 Discovery of genomic causes of disease and development of diagnostics and therapeutics 2014 (7) Charles Lee Scientific director 7 MannKind Corp. 1 Casper St. Danbury, CT 06810 203-798-8000; www.mannkindcorp.com Valencia, CA 117 Inhalation product technologies 1991 Matthew J. Pfeffer CEO, CFO & director 8 Protein Sciences Corp. (8) Meriden Meriden, CT 88 Vaccine development and protein production 1983 Manon M. J. Cox (9) Transition taskforce leader 9 Achillion Pharmaceuticals 300 George St. New Haven, CT 06511 203-624-7000; www.achillion.com New Haven, CT 80 Therapy for chronic hepatitis C and a platform of specific complement factor D inhibitors 2000 Milind S. Deshpande President & CEO 10 Core Informatics (10) 36 E. Industrial Road, 2nd floor Branford, CT 06405 866-823-0337; www.coreinformatics.com Branford, CT 70 Data management and lab informatics solutions built on the platform for science 2005 Josh Geballe CEO 11 Transgenomic Inc. (11) 5 Science Park New Haven, CT 06511 203-907-2201; www.transgenomic.com Omaha, NE 55 Genetic testing 1997 Paul Kinnon President & CEO 12 Ce3 Inc. 246 Goose Lane, Suite 202 Guilford, CT 06437 203-404-7500; www.ce3inc.com Guilford, Clinton CT 47 Contract research focused on providing biotechnology companies with phase 1 and 2 clinical trial execution and regulatory submission services 2005 Holly Ohanesian Coulter President & CEO 13 Arvinas Inc. 5 Science Park New Haven, CT 06511 203-535-1456; www.arvinas.com New Haven, CT 42 (12) Development of therapeutics to treat a variety of diseases including cancer, pro-inflammatory, autoimmune and rare disease 2013 Manuel Litchman President & CEO 14 Melinta Therapeutics Inc. (11) 300 George St., Suite 301 New Haven, CT 06511 203-624-5606; www.melinta.com Lincolnshire, IL 40 Discovery, development and commercialization of antibiotics to overcome resistant, life-threatening infections 2000 Eugene Sun CEO 15 CARA Therapeutics (13) 107 Elm St., 9th Floor, 4 Stamford Plaza Stamford, CT 06902 203-406-3700; www.caratherapeutics.com Stamford, CT 39 Development of therapeutics to treat human diseases associated with pain, inflammation and pruritus 2004 Derek Chalmers Director, president & CEO 16 NanoViricides Inc. 1 Controls Drive Shelton, CT 06484 203-937-6137; www.nanoviricides.com Shelton, CT 30 Nanotechnology-based biomimetic anti-viral medicines targeting influenzas, bird flu, HIV/AIDS, cold sores, genital herpes infection, viral eye diseases, ebola and dengue viruses 2005 Eugene Seymour, CEO Anil R. Diwan President & chairman 17 Celldex Therapeutics Inc. (14) 688 East Main St., Suite 1A Branford, CT 06405 203-483-3500; celldex.com Hampton, NJ 29 Immunotherapy, therapeutic antibodies, antibody drug conjugates, immune system modulators 2005 Anthony Marucci President & CEO 18 Biohaven Pharmaceutical Holding Co. LTD 234 Church St. New Haven, CT 06510 203-404-0410; biohavenpharma.com New Haven, CT 24 Acute treatment of migraine and amyotrophic lateral sclerosis 2013 Vlad Coric CEO Source: BioCT, each company via survey. Notes: R&D = research and development, DND = did not disclose. Hologic Inc., Medtronic and New Haven Pharmaceuticals do not disclose employee data by geographic location. AxioMx Inc. (Abcam plc), Becton Dickinson, Charles River Laboratories International Inc., CooperSurgical Inc., Gilead Connecticut Inc., Icahn School of Medicine Mount Sinai Genomics Research Center and IDEXX Laboratories were contacted but did not complete a survey. Stamford's Purdue Pharma LP last responded to the survey in 2015, reporting 500 employees statewide. (1) 244 Connecticut employees were laid off in 2016. (2) As of Sept. 2017, the company plans to move its headquarters to Boston, Mass., and keep 450 employees in New Haven. (3) Figure based on Jan. 2017 survey response, a March 2017 reduction in workforce and company news reports and announcements as of Sept. 2017. (4) In Dec. 2016, BMS announced previous plans to close Wallingford site by the end of 2018 are still in play, but the Connecticut development site that was to be built is no longer on the drawing board. (5) With an additional R&D operation in Branford. (6) Nonprofit residing on the campus of University of Connecticut Health Center. (7) Year founded for the Farmington site. The Jackson Laboratory was founded in 1929. (8) Paris-based Sanofi acquired Protein Sciences Corp., effective Aug. 28, 2017; under the terms of the agreement, Sanofi will make an upfront payment of $650 million and pay up to $100 million upon achievement of certain milestones. (9) Served as president & CEO from April 2010 until the recent Sanofi acquisition. (10) Acquired by Waltham, Mass.-based Thermo Fisher Scientific Inc. in March 2017. (11) Data from 2016 survey. (12) Jan. 19, 2018, announced expansion plans that will bring 30 additional jobs to New Haven. (13) Relocated from Shelton to Stamford. (14) New Haven's Kolltan Pharmaceuticals Inc. was acquired by Celldex Therapeutics on Nov. 29, 2016. —Compiled by Stephanie R. Meagher.